Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1691.15% is 69% above its 5-year average of -5502.27%, near the high end of its 5-year range (-24251.50%–-45.36%).
20.48% below its 12-month average of -1403.62%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1183.40%.
EBITDA MARGIN
-1691.15%
EBITDA MARGIN AVG TTM
-1403.62%
EBITDA MARGIN AVG 3Y
-2923.67%
EBITDA MARGIN AVG 5Y
-5502.27%
EBITDA MARGIN AVG 10Y
-3969.06%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-20.48%
CURRENT VS 3Y AVG
+42.16%
CURRENT VS 5Y AVG
+69.26%
CURRENT VS 10Y AVG
+57.39%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cibus, Inc.
Market Cap
$128.24M
EBITDA Margin
-1691.15%
TTM Avg
-1403.62%
3Y Avg
-2923.67%
5Y Avg
-5502.27%
Market Cap
$129.14M
EBITDA Margin
-27378.57%
TTM Avg
-16324.37%
3Y Avg
-14117.74%
5Y Avg
-9505.20%
Market Cap
$134.74M
EBITDA Margin
5.24%
TTM Avg
5.41%
3Y Avg
5.74%
5Y Avg
10.79%
Market Cap
$118.63M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$118.02M
EBITDA Margin
-1187.82%
TTM Avg
-1407.84%
3Y Avg
-970.99%
5Y Avg
-809.42%
Market Cap
$117.43M
EBITDA Margin
-254.86%
TTM Avg
-347.69%
3Y Avg
-398.28%
5Y Avg
-4102.41%
Market Cap
$142.11M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cibus, Inc. (CBUS) | $128.24M | -1691.15% | -1403.62% | -2923.67% | -5502.27% |
| Entera Bio Ltd. (ENTX)vs › | $129.14M | -27378.57% | -16324.37% | -14117.74% | -9505.20% |
| enGene Holdings Inc. (ENGN)vs › | $125.27M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | 5.24% | 5.41% | 5.74% | 10.79% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| BGM Group Ltd. (BGM)vs › | $118.63M | -29.32% | -13.32% | -6.17% | -1.07% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -1187.82% | -1407.84% | -970.99% | -809.42% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | -254.86% | -347.69% | -398.28% | -4102.41% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -221.15% | -221.15% | -221.15% | -221.15% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $114.24M | N/A | N/A | N/A | N/A |
Gross Margin
-62.8%
EBITDA Margin
-1691.2%
Operating Margin
-1853.9%
Net Margin
-2258.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1183.40% |
| 2026-03-31 | -649.79% |
| 2025-12-31 | -1150.90% |
| 2025-09-30 | -2279.35% |
| 2025-06-30 | -1754.66% |
| 2025-03-31 | -3862.38% |
| 2024-12-31 | -1351.16% |
| 2024-09-30 | -13737.39% |
| 2024-06-30 | -2356.68% |
| 2024-03-31 | -3061.65% |
| 2023-12-31 | -24251.50% |
| 2023-09-30 | -5076.42% |
| 2023-06-30 | -9434.01% |
| 2023-03-31 | -9469.05% |
| 2022-12-31 | -6992.86% |
| 2022-09-30 | -13828.57% |
| 2022-06-30 | -15541.46% |
| 2022-03-31 | -17871.88% |
| 2021-12-31 | -316.42% |
| 2021-09-30 | -81.95% |
| 2021-06-30 | -45.36% |
| 2021-03-31 | -206.63% |
| 2020-12-31 | -89.69% |
| 2020-09-30 | -163.75% |
| 2020-06-30 | -459.30% |
| 2020-03-31 | -429.28% |
| 2019-12-31 | -301.62% |
| 2019-09-30 | -348.20% |
| 2019-06-30 | -2241.42% |
| 2019-03-31 | -4573.89% |
| 2018-12-31 | -413700.00% |
| 2018-09-30 | -27196.30% |
| 2018-06-30 | -3712.76% |
| 2018-03-31 | -37636.36% |
| 2017-12-31 | -3589.25% |
| 2017-09-30 | -29093.18% |
| 2017-06-30 | -1392.38% |
| 2017-03-31 | -4829.09% |
| 2016-12-31 | -6077.78% |
| 2016-09-30 | -2289.52% |
| 2016-06-30 | -2136.21% |
| 2016-03-31 | -2364.15% |
